Skip to main
  1. Stocks
  2. Cartesian Therapeutics Inc
  3. Forecast
RNAC

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics is positioned favorably because repeated Descartes-08 dosing produced durable, clinically meaningful benefit: all 5 retreated patients improved, with mean Month 12 MG-ADL and MGC reductions of 6.6 and 15.0 points, respectively, after a median 16.6 months between courses. The absence of CRS, ICANS, cytopenias, hypogammaglobulinemia, or retreatment SAEs supports a differentiated, chemo-free outpatient platform that may fit patients who need intermittent disease control without lymphodepletion. Its broader appeal is reinforced by competitive data showing strong but conditioning-dependent benchmarks, while Cartesian’s approach could deliver sustained efficacy with less treatment burden and a favorable cash buffer over $4.50 per share.

Bears say

Cartesian Therapeutics is a high-risk clinical-stage biopharmaceutical company whose valuation depends heavily on the success of Descartes-08 and other pipeline candidates, making clinical or regulatory failure a central downside risk. Its lead programs may fail to show meaningful efficacy, durable or re-treatable benefit, or acceptable safety, while manufacturing and shipment of cell therapy products could create logistical and technical bottlenecks that disrupt development and commercialization. Even if clinical data improve, regulatory delays, competition from current and future therapies, and an inability to achieve sales estimates could limit market uptake and financing flexibility, reinforcing a negative fundamental outlook.

RNAC has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

RNAC Analyst Forecast & Price Prediction

Get the latest RNAC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RNAC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 5 analysts, RNAC has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


RNAC Analyst Forecast & Price Prediction

Get the latest RNAC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RNAC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RNAC stock data and trends